The effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis

被引：0
|
作者：
Tice, Jeffrey A. [1 ]
Touchette, Daniel R. [2 ]
Lien, Pei-Wen [2 ]
Agboola, Foluso [3 ]
Nikitin, Dmitriy [3 ]
Pearson, Steven D. [3 ]
机构：
[1] Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA
[2] Univ Illinois, Coll Pharm, Chicago, IL USA
[3] ICER, Boston, MA USA
来源：
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY | 2022年 / 28卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
引用
收藏
页码：119 / 124
页数：6
相关论文
共 50 条
  • [21] EFFECTIVENESS OF EFGARTIGIMOD IN PATIENT WITH MYASTHENIA GRAVIS AND TUMOR: A SINGLE CENTER EXPERIENCE
    Ruan, Zhe
    Chang, Ting
    Hao, Sijia
    Gao, Ting
    Tang, Yonglan
    Huang, Xiaoxi
    Cao, Xiangqi
    MUSCLE & NERVE, 2024, 70 (03) : 588 - 588
  • [22] Efgartigimod: A Review in Generalised Myasthenia Gravis
    Blair, Hannah A.
    DRUGS, 2024, 84 (11) : 1463 - 1474
  • [23] Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis
    Oyama, Munenori
    Okada, Kensuke
    Masuda, Masayuki
    Shimizu, Yuko
    Yokoyama, Kazumasa
    Uzawa, Akiyuki
    Kawaguchi, Naoki
    Ikeguchi, Ryotaro
    Hoshino, Yasunobu
    Hatano, Taku
    Ozawa, Yukiko
    Nakahara, Jin
    Aizawa, Hitoshi
    Kitagawa, Kazuo
    Hattori, Nobutaka
    Kuwabara, Satoshi
    Murai, Hiroyuki
    Suzuki, Shigeaki
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2020, 13
  • [24] Efgartigimod in refractory autoimmune myasthenia gravis
    Remijn-Nelissen, Linda
    Tannemaat, Martijn R.
    Ruiter, Annabel M.
    Campman, Yvonne J. M.
    Verschuuren, Jan J. G. M.
    MUSCLE & NERVE, 2024, 70 (03) : 325 - 332
  • [25] Cellular changes in eculizumab early responders with generalized myasthenia gravis
    Li, Yingkai
    Yi, John S.
    Howard, James F.
    Chopra, Manisha
    Russo, Melissa A.
    Guptill, Jeffrey T.
    CLINICAL IMMUNOLOGY, 2021, 231
  • [26] Efgartigimod alfa (Vyvgart) for Myasthenia Gravis
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2022, 64 (1648): : 62 - 63
  • [27] ALTERNATIVE DOSING OF EFGARTIGIMOD IN MYASTHENIA GRAVIS
    Malatesta, Lindsay
    Kohno, Kyoko
    Renwick, Rachel
    Lee, Christopher
    MUSCLE & NERVE, 2024, 70 (03) : 719 - 719
  • [28] OUTCOMES FOR PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS PRESCRIBED RAVULIZUMAB, ECULIZUMAB, OR EFGARTIGIMOD TREATMENT: INTERIM ANALYSIS OF A RETROSPECTIVE MEDICAL RECORD ANALYSIS (ELEVATE)
    Scheiner, Christopher A.
    Macwan, Samir P.
    Streicher, Nicholas
    Yee, Karen S.
    Sader, Chloe
    Blackowicz, Michael
    Numapau, Nana
    Gentile, Danielle
    Sharpe, Jason
    Pathak, Prathamesh
    Pulley, Michael T.
    MUSCLE & NERVE, 2024, 70 (03) : 695 - 696
  • [29] A real world experience with Efgartigimod in generalized Myasthenia Gravis in a national reference center
    Antozzi, C.
    Frangiamore, R.
    Rinaldi, E.
    Vanoli, F.
    Andreetta, F.
    Ciusani, E.
    Bonanno, S.
    Maggi, L.
    Gallone, A.
    Pinna, A.
    Mantegazza, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 204 - 204
  • [30] Efgartigimod alfa-the importance of FcRn blockade in the treatment of generalized myasthenia gravis
    Bozovsky, Tomas
    Ehler, Edvard
    CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2023, 86 (03) : 214 - 217
12345